"Pembrolizumab in Addition to Paclitaxel and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer"@en . "2023-06-30T00:00:00Z"^^ . . . . "clinical trial"@en . . . . "A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer"@en . "ensayu cl\u00EDnicu"@ast . . . . . "2019-04-26T00:00:00Z"^^ . . . . "\u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0432\u0438\u043F\u0440\u043E\u0431\u0443\u0432\u0430\u043D\u043D\u044F"@uk . . . . . . "klinisch onderzoek"@nl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "810"^^ . . . . . "Pembrolizumab in Addition to Paclitaxel and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer"@en . . . . . . . . . . . . . . . . . . . "Pembrolizumab in Addition to Paclitaxel and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer"@en . . . . . . . . . . . . . "NCT03914612" . "18"^^ . . . . . . . . . . . . . . . . . . . . . . . . . . . .